NEW YORK, June 12 – Affymetrix stock was down $14.10, or 34 percent, at $26.85 in afternoon trading on Tuesday, following an announcement on Monday after the close of trading that the company was slashing its second quarter revenue expectations.

The company said its revenues for the quarter would total between $44 million and $50 million, a drop of between $6 million and $14 million from previous estimates.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.

The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.

Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.

In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.